Literature DB >> 24707347

Truncated Orexin Peptides: Structure-Activity Relationship Studies.

Nadezhda A German1, Ann M Decker1, Brian P Gilmour1, Brian F Thomas1, Yanan Zhang1.   

Abstract

Orexin receptors are involved in many processes including energy homeostasis, wake/sleep cycle, metabolism and reward. Development of potent and selective ligands is an essential step for defining the mechanism(s) underlying such critical processes. The goal of this study was to further investigate the structure-activity relationships of these peptides and to identify truncated form of the orexin peptides active at OX1. Truncation studies have led to OXA (17-33) as the shortest active peptide known to date with a 23-fold selectivity for OX1 over OX2. Alanine, D-amino acid and proline scans have highlighted the particular importance of Tyr17, Leu20, Asn25 and His26 for agonist properties of OXA(17-33). The conformation of the C-terminus might also be a defining factor in agonist activity and selectivity of the orexin peptides for the OX1 receptor.

Entities:  

Keywords:  Orexin; Peptide; Structure-activity relationship

Year:  2013        PMID: 24707347      PMCID: PMC3975045          DOI: 10.1021/ml400333a

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  28 in total

1.  Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction.

Authors:  Jaana Putula; Pauli M Turunen; Lisa Johansson; Johnny Näsman; Runar Ra; Laura Korhonen; Jyrki P Kukkonen
Journal:  FEBS Lett       Date:  2011-04-15       Impact factor: 4.124

2.  The NMR-derived conformation of orexin-A: an orphan G-protein coupled receptor agonist involved in appetite regulation and sleep.

Authors:  Mark Miskolzie; George Kotovych
Journal:  J Biomol Struct Dyn       Date:  2003-10

Review 3.  Orexin receptor antagonists: a new concept in CNS disorders?

Authors:  John Gatfield; Catherine Brisbare-Roch; Francois Jenck; Christoph Boss
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

Review 4.  Physiology of the orexinergic/hypocretinergic system: a revisit in 2012.

Authors:  Jyrki P Kukkonen
Journal:  Am J Physiol Cell Physiol       Date:  2012-10-03       Impact factor: 4.249

Review 5.  Orexin receptors as therapeutic drug targets.

Authors:  Anthony L Gotter; Anthony J Roecker; Richard Hargreaves; Paul J Coleman; Christopher J Winrow; John J Renger
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

6.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

7.  Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.

Authors:  R M Chemelli; J T Willie; C M Sinton; J K Elmquist; T Scammell; C Lee; J A Richardson; S C Williams; Y Xiong; Y Kisanuki; T E Fitch; M Nakazato; R E Hammer; C B Saper; M Yanagisawa
Journal:  Cell       Date:  1999-08-20       Impact factor: 41.582

Review 8.  Orexin receptor antagonists: medicinal chemistry and therapeutic potential.

Authors:  Anthony J Roecker; Paul J Coleman
Journal:  Curr Top Med Chem       Date:  2008       Impact factor: 3.295

Review 9.  Role of orexin/hypocretin in dependence and addiction.

Authors:  Ruth Sharf; Maysa Sarhan; Ralph J Dileone
Journal:  Brain Res       Date:  2009-08-20       Impact factor: 3.252

10.  NMR conformational studies of micelle-bound orexin-B: a neuropeptide involved in the sleep/awake cycle and feeding regulation.

Authors:  Mark Miskolzie; Scott Lucyk; George Kotovych
Journal:  J Biomol Struct Dyn       Date:  2003-12
View more
  8 in total

Review 1.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

2.  Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.

Authors:  Jie Yin; Kerim Babaoglu; Chad A Brautigam; Lindsay Clark; Zhenhua Shao; Thomas H Scheuermann; Charles M Harrell; Anthony L Gotter; Anthony J Roecker; Christopher J Winrow; John J Renger; Paul J Coleman; Daniel M Rosenbaum
Journal:  Nat Struct Mol Biol       Date:  2016-03-07       Impact factor: 15.369

3.  Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis.

Authors:  Pascal Nicole; Pierre Couvineau; Nadege Jamin; Thierry Voisin; Alain Couvineau
Journal:  Br J Pharmacol       Date:  2015-09-30       Impact factor: 8.739

Review 4.  A Review of Single-Nucleotide Polymorphisms in Orexigenic Neuropeptides Targeting G Protein-Coupled Receptors.

Authors:  Mark D Ericson; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2018-05-11       Impact factor: 4.418

5.  Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.

Authors:  Dehui Zhang; David A Perrey; Ann M Decker; Tiffany L Langston; Vijayakumar Mavanji; Danni L Harris; Catherine M Kotz; Yanan Zhang
Journal:  J Med Chem       Date:  2021-06-08       Impact factor: 7.446

6.  HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy.

Authors:  Noriaki Sakai; Mari Matsumura; Ling Lin; Emmanuel Mignot; Seiji Nishino
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

7.  Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study.

Authors:  Lasse Karhu; Aniket Magarkar; Alex Bunker; Henri Xhaard
Journal:  J Phys Chem B       Date:  2019-03-18       Impact factor: 2.991

Review 8.  The Orexin receptors: Structural and anti-tumoral properties.

Authors:  Alain Couvineau; Pascal Nicole; Valérie Gratio; Thierry Voisin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-28       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.